Regulation, generic competition and pharmaceutical prices : theory and evidence from a natural experiment
Autor(a) principal: | |
---|---|
Data de Publicação: | 2008 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/1822/11663 |
Resumo: | We study the impact of regulatory regimes on generic competition and pharmaceutical pricing using a unique policy experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub-sample of off-patent products. We exploit a detailed panel dataset at product level covering a wide set of off-patent drugs before and after the policy reform. Off-patent drugs not subject to reference pricing serve as our control group. We find that RP leads to lower relative prices, with the effect being driven by strong brand-name price reductions, and not increases in generic prices. We also find that RP increases generic competition, resulting in lower brand-name market shares. Finally, we show that RP has a strong negative effect on average prices at molecule level, suggesting significant cost-savings. |
id |
RCAP_ab3722b5cc1e5de3a41ba3d134201b29 |
---|---|
oai_identifier_str |
oai:repositorium.sdum.uminho.pt:1822/11663 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Regulation, generic competition and pharmaceutical prices : theory and evidence from a natural experimentPharmaceuticalsRegulationGeneric competitionWe study the impact of regulatory regimes on generic competition and pharmaceutical pricing using a unique policy experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub-sample of off-patent products. We exploit a detailed panel dataset at product level covering a wide set of off-patent drugs before and after the policy reform. Off-patent drugs not subject to reference pricing serve as our control group. We find that RP leads to lower relative prices, with the effect being driven by strong brand-name price reductions, and not increases in generic prices. We also find that RP increases generic competition, resulting in lower brand-name market shares. Finally, we show that RP has a strong negative effect on average prices at molecule level, suggesting significant cost-savings.Fundação para a Ciência e a Tecnologia (FCT) - Programa Operacional Ciência e Inovação 2010 (POCI 2010)Fundo Europeu de Desenvolvimento Regional (FEDER)Universidade do Minho. Núcleo de Investigação em Políticas Económicas (NIPE)Universidade do MinhoBrekke, Kurt R.Holmås, Tor HelgeStraume, Odd Rune20082008-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/1822/11663engBREKKE, Kurt R. ; HOLMAS, Tor Helge; STRAUME, Odd Rune – “Regulation, generic competition and pharmaceutical prices : theory and evidence from a natural experiment” [Em linha]. Braga : Núcleo de Investigação em Políticas Económicas, 2008. [Consult. 7 Fev. 2011]. Disponível em WWW:<URL:http://www3.eeg.uminho.pt/economia/nipe/docs/2008/NIPE_WP_1_2008.PDF>.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-21T12:05:18Zoai:repositorium.sdum.uminho.pt:1822/11663Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T18:55:43.093980Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Regulation, generic competition and pharmaceutical prices : theory and evidence from a natural experiment |
title |
Regulation, generic competition and pharmaceutical prices : theory and evidence from a natural experiment |
spellingShingle |
Regulation, generic competition and pharmaceutical prices : theory and evidence from a natural experiment Brekke, Kurt R. Pharmaceuticals Regulation Generic competition |
title_short |
Regulation, generic competition and pharmaceutical prices : theory and evidence from a natural experiment |
title_full |
Regulation, generic competition and pharmaceutical prices : theory and evidence from a natural experiment |
title_fullStr |
Regulation, generic competition and pharmaceutical prices : theory and evidence from a natural experiment |
title_full_unstemmed |
Regulation, generic competition and pharmaceutical prices : theory and evidence from a natural experiment |
title_sort |
Regulation, generic competition and pharmaceutical prices : theory and evidence from a natural experiment |
author |
Brekke, Kurt R. |
author_facet |
Brekke, Kurt R. Holmås, Tor Helge Straume, Odd Rune |
author_role |
author |
author2 |
Holmås, Tor Helge Straume, Odd Rune |
author2_role |
author author |
dc.contributor.none.fl_str_mv |
Universidade do Minho |
dc.contributor.author.fl_str_mv |
Brekke, Kurt R. Holmås, Tor Helge Straume, Odd Rune |
dc.subject.por.fl_str_mv |
Pharmaceuticals Regulation Generic competition |
topic |
Pharmaceuticals Regulation Generic competition |
description |
We study the impact of regulatory regimes on generic competition and pharmaceutical pricing using a unique policy experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub-sample of off-patent products. We exploit a detailed panel dataset at product level covering a wide set of off-patent drugs before and after the policy reform. Off-patent drugs not subject to reference pricing serve as our control group. We find that RP leads to lower relative prices, with the effect being driven by strong brand-name price reductions, and not increases in generic prices. We also find that RP increases generic competition, resulting in lower brand-name market shares. Finally, we show that RP has a strong negative effect on average prices at molecule level, suggesting significant cost-savings. |
publishDate |
2008 |
dc.date.none.fl_str_mv |
2008 2008-01-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/1822/11663 |
url |
http://hdl.handle.net/1822/11663 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
BREKKE, Kurt R. ; HOLMAS, Tor Helge; STRAUME, Odd Rune – “Regulation, generic competition and pharmaceutical prices : theory and evidence from a natural experiment” [Em linha]. Braga : Núcleo de Investigação em Políticas Económicas, 2008. [Consult. 7 Fev. 2011]. Disponível em WWW:<URL:http://www3.eeg.uminho.pt/economia/nipe/docs/2008/NIPE_WP_1_2008.PDF>. |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade do Minho. Núcleo de Investigação em Políticas Económicas (NIPE) |
publisher.none.fl_str_mv |
Universidade do Minho. Núcleo de Investigação em Políticas Económicas (NIPE) |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799132343366057984 |